

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/028578 A1

- (51) International Patent Classification⁷: **A61L 27/14** (74) Agent: LEE, Won-Hee; 8th Fl., Sung-ji Heights II, 642-16 Yoksam-dong, Kangnam-ku, 135-080 Seoul (KR).
- (21) International Application Number: **PCT/KR2002/001837** (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: **30 September 2002 (30.09.2002)**
- (25) Filing Language: **Korean**
- (26) Publication Language: **English**
- (71) Applicant (*for all designated States except US*): **REGEN BIOTECH, INC.** [KR/KR]; C9231 KIST, 39-1 Hawolgok-dong, Sungbuk-ku, 136-791 Seoul (KR).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **KIM, In-San** [KR/KR]; #106-908 Dongsu Town, 1040 Maeho-dong, Soosung-ku, 706-140 Taegu (KR). **CHO, Byung, Chae** [KR/KR]; #103-102 Dongsu-Myungmoon Town, 303 Bumou 4-dong, Soosung-ku, 706-822 Taegu (KR).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— *with international search report*

[Continued on next page]

(54) Title: COMPOSITION FOR STIMULATING BONE-FORMATION AND BONE CONSOLIDATION



(57) Abstract: The present invention relates to a composition for stimulating bone-formation and bone-consolidation, more particularly, to a composition for stimulating bone-formation and bone-consolidation by adding a material for stimulating bone-forming and bone-consolidation to the mixture of tripolyphosphate and water-soluble chitosan. The composition of the present invention can stimulate bone-formation and bone-consolidation in early stages.

WO 2004/028578 A1

BEST AVAILABLE COPY

WO 2004/028578 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

COMPOSITION FOR STIMULATING BONE-FORMATION
AND BONE-CONSOLIDATION

FIELD OF THE INVENTION

5 The present invention relates to a composition
for stimulating bone-formation and bone-consolidation,
more particularly, to a composition for stimulating
bone-formation and bone-consolidation by adding a
material for stimulating bone-forming and bone-
10 consolidation to the mixture of tripolyphosphate and
water-soluble chitosan.

BACKGROUND ART OF THE INVENTION

15 Bone-loss is often caused by a disease or a car
accident recently, so that supplementing bone-loss is
importantly required. Bone-transplantation is one way
to supplement bone-loss and more preferably bone-
filling composition is used. Bone-extension technique
is performed today to extend one's height or to correct
20 undersized jaws, for which bone-filling composition is
also required a lot.

Bone-extension technique is to stimulate bone-
growth, especially growth in height, by stretching

based on the theory that "Tension forces stimulate histogenesis". Bone-extension technique was first devised for the growth of limb bones but has been widely used for jawbone extension. Jawbone extension method is one of techniques performed in the field of cranial jaw facial surgery, which can improve facial ratio not by cutting bone but by moving facial bones gradually by fixing bone-stretching apparatus to retreated parts of jawbone and central facial form.

Bone-extension technique has been successfully used for supplementing the loss of long bone since Ilizarov found out biomechanical elements for bone-extension (Ilizarov GA, *J. Dis. Orthop. Inst.*, 48(1): 1, 1988; Ilizarov GA, *Clin. Ortho.*, 239: 263, 1989; Ilizarov GA, *Clin. Ortho.*, 238: 249, 1989). It is important for performing the successful bone-extension to keep blood circulation in the part of bone-extension well and to fix external fixator stably to both sides of joint part of cortical bone, resulting in the stimulation of bone-consolidation by gradual extension of bone (White SH, *J. Bone Joint Surgery*, 72-B: 350, 1990; White SH, *Orthop. Clin. North. Amer.*, 22: 569, 1991; Fishgrund J., Paley D., Sulter D., *Clin. Orthop.*, 301: 31, 1994).

The period of bone-consolidation depends on

extension part of bones such as facial bone or long bone, blood circulation condition, the age of a patient, etc. Bone-consolidation of craniofacial bone takes 3-5 weeks for children and 6-12 weeks for adults after bone-extension, while it takes 3-6 months in long bone regardless of age. Performing bone-extension for craniofacial bone has a couple of problems; one is carrying high possibility of complications and the other is postponing the return to normal life due to the long bone-consolidation time. Precisely, the treatment after bone-extension takes 2-4 months composing of latent phase, bone-extension phase and bon-consolidation phase.

According to Charls and Sailer's report, extending 1 mm a day shows stronger biochemical and physiological characteristics than extending 2-3 mm a day (Carls & Sailer, *J. Craniomaxillofac Surg.*, 94: 152, 1994). Ilizarov has also reported that extending 1 mm a day showed best results while extending 0.5 mm a day caused premature bone-consolidation and extending 2 mm a day caused undesirable changes in extended tissues (Ilizarov, *J. Dis. Orthop. Inst.*, 48(1): 1, 1988; Ilizarov, *Clin. Ortho* 239: 263, 1989). In addition, it has also been known that consecutive extending causes the least damage in tissues but the best development of

capillary vessels and bone-formation. Therefore, shortening the period of bone-extension and bone-consolidation can contribute to prevent possible complications and to make a patient return to normal life early. In order to shorten the period of bone-extension and bone-consolidation, bone-filling composition is used to stimulate bone-formation and bone-consolidation.

Meanwhile, autobone-graft, treated homograft, heterograft and bone graft substitute have been known to stimulate bone-formation. Autobone-graft is used for the treatment of joint-agglutination or non-agglutination fracture, or for avoiding damage and void caused by infection, tumor and operation by supplementing bone cavity or bone loss. Transplanted autobone is well adsorbed, resulting in re-circulation of blood. At this time, osteoprogenitor cells are differentiated to bony osteogenesis cells and the activation thereof stimulates bone-regeneration as well as treats bone-loss. However, autobone-graft has problems such as limitation in the amount of extraction and high morbidity caused by the secondary operation for the part of donation. Thus, bone morphogenic protein or other bone-grafting substitute is used to induce bone-regeneration at extended sites. Bone

morphogenic protein is regarded as the strongest bone-inducing material but is limited in clinical use because it is very expensive and hard to obtain.

5 Thus, the present inventors have been tried to find out a composition to stimulate bone-formation and bone-consolidation that is inexpensive and suitable for human. As a result, we, the present inventors, have prepared a composition by adding a material stimulating
10 bone-formation and bone-consolidation to the mixture of tripolyphosphate and water soluble chitosan, and have completed the present invention by confirming that the composition stimulates bone-consolidation in the early phase and shortens the period of bone-generation by
15 cutting bone-consolidation time.

SUMMARY OF THE INVENTION

The present invention relates to a composition for stimulating bone-formation and bone-consolidation, more particularly, to a composition for stimulating
20 bone-formation and bone-consolidation by adding a material for stimulating bone-formation and bone-consolidation to the mixture of tripolyphosphate and water-soluble chitosan. The composition of the present

invention can stimulate bone-formation and bone-consolidation in the early stage.

BRIEF DESCRIPTION OF THE DRAWINGS

5 FIG. 1 is a photograph showing the performance of vertical osteotomy at left jaw of a dog for bone-extension with chitosan, β ig-h3 and human bone morphogenic protein (BMP-4),

10 FIG. 2 is a photograph showing a dual syringe containing water-soluble chitosan, water-soluble chitosan containing β ig-h3, water soluble chitosan containing BMP-4, and 5% tripolyphosphate,

 A : 0.5 cc of water soluble chitosan, water
15 soluble chitosan containing β ig-h3, or water soluble chitosan containing BMP-4

 B : 0.5 cc of 5% tripolyphosphate

 FIG. 3 is a photograph showing a dog in the
20 death-imminent state, seven weeks after bone extension,

 FIG. 4A is a photograph showing the extent of bone-consolidation in a control group that was measured with radio-assay five weeks after bone extension,

particularly the control group was treated with only tripolyphosphate and was induced to have 2.0 mm extension per day for five days for the group,

5 FIG. 4B is a photograph showing the extent of bone-consolidation in a control group that was measured with radio-assay seven weeks after bone extension, particularly the control group was treated with only tripolyphosphate and was induced to have 2.0 mm
10 extension per day for five days,

FIG. 5A is a photograph showing the extent of bone-consolidation in a chitosan group that was measured with radio-assay 4 weeks after bone extension,
15 particularly the group was treated with chitosan and tripolyphosphate, and was induced to have 2.0 mm extension per day for 5 days,

FIG. 5B is a photograph showing the extent of
20 bone-consolidation in a chitosan group that was measured with radio-assay 7 weeks after bone extension, particularly the group was treated with chitosan and tripolyphosphate, and was induced to have 2.0 mm extension per day for 5 days,

25

FIG. 6A is a photograph showing the extent of bone-consolidation in a β ig-h3 group that was measured with radio-assay 4 weeks after bone extension, particularly the group was treated with water-soluble
5 chitosan containing β ig-h3 and tripolyphosphate, and was induced to have 2.0 mm extension per day for 5 days,

FIG. 6B is a photograph showing the extent of bone-consolidation in a β ig-h3 group that was measured
10 with radio-assay 7 weeks after bone extension, particularly the group was treated with water-soluble chitosan containing β ig-h3 and tripolyphosphate, and was induced to have 2.0 mm extension per day for 5 days,

15 FIG. 7A is a photograph showing the extent of bone-consolidation in a BMP-4 group that was measured with radio-assay 4 weeks after bone extension, particularly the group was treated with water-soluble chitosan containing BMP-4 and tripolyphosphate, and was
20 induced to have 2.0 mm extension per day for 5 days,

FIG. 7B is a photograph showing the extent of bone-consolidation in a BMP-4 group that was measured with radio-assay 7 weeks after bone extension,
25 particularly the group was treated with water-soluble

chitosan containing BMP-4 and tripolyphosphate, and was induced to have 2.0 mm extension per day for 5 days,

FIG. 8A is a graph showing the mineral density of bone 4 weeks after bone extension for each group that was injected with chitosan only, water soluble chitosan containing β ig-h3 and water soluble chitosan containing BMP-4 respectively, and was induced to have 2.0 mm extension per day for 5 days,

10

FIG. 8B is a graph showing the mineral density of bone 7 weeks after bone extension for each group that was injected with chitosan only, water soluble chitosan containing β ig-h3 and water soluble chitosan containing BMP-4, and was induced to have 2.0 mm extension per day for 5 days,

15

FIG. 9A is a photograph showing the histological section of a control group 4 weeks after bone extension, particularly the group was injected with tripolyphosphate only and was induced to have 2.0 mm extension per day for 5 days,

20

Arrows: the first cutting parts

FIG. 9B is a photograph showing the histological

25

section of a control group 7 weeks after bone extension, particularly the group was injected with tripolyphosphate only and was induced to have 2.0 mm extension per day for 5 days,

5 Arrows: the first cutting parts

FIG. 9C is a photograph showing the new bone-formation at the edge of bone extension region in a control group injected tripolyphosphate only and
10 induced to have 2.0 mm extension per day for 5 days, which was confirmed by hematoxylin & eosin staining,

A: fibrous tissue, B: osteoblasts

FIG. 10A is a photograph showing the histological
15 section of a BMP-4 group 4 weeks after bone extension, particularly the group was injected with water soluble chitosan containing BMP-4 and tripolyphosphate, and was induced to have 2.0 mm extension per day for 5 days,

Arrows: the first cutting parts

20

FIG. 10B is a photograph showing the histological section of a BMP-4 group 7 weeks after bone extension, particularly the group was injected with water soluble chitosan containing BMP-4 and tripolyphosphate, and was
25 induced to have 2.0 mm extension per day for 5 days,

Arrows: the first cutting parts

FIG. 10C is a photograph showing that the center of the extended region was filled with osteoblasts and fibrous tissues, which was confirmed by hematoxylin & eosin staining with the histological section of A,

FIG. 10D is a photograph showing that the center of the extended region was filled with osteoblasts and fibrous tissues, which was confirmed by hematoxylin & eosin staining with the histological section of B,

FIG. 11A is a photograph showing the histological section of a β ig-h3 group 4 weeks after bone extension, particularly the group was injected with water soluble chitosan containing β ig-h3 and tripolyphosphate, and was induced to have 2.0 mm extension per day for 5 days,

Arrows: the first cutting parts

FIG. 11B is a photograph showing the histological section of a β ig-h3 group 7 weeks after bone extension, particularly the group was injected with water soluble chitosan containing β ig-h3 and tripolyphosphate, and was induced to have 2.0 mm extension per day for 5 days,

Arrows: the first cutting parts

FIG. 11C is a photograph showing the new bone-formation over the whole extended region, which was confirmed by hematoxylin & eosin staining with the histological section of B,

FIG. 12A is a photograph showing the histological section of a chitosan group 4 weeks after bone extension, particularly the group was injected with chitosan and tripolyphosphate, and was induced to have 2.0 mm extension per day for 5 days,

Arrows: the first cutting parts

FIG. 12B is a photograph showing the histological section of a chitosan group 7 weeks after bone extension, particularly the group was injected with chitosan and tripolyphosphate, and was induced to have 2.0 mm extension per day for 5 days,

Arrows: the first cutting parts

FIG. 12C is a photograph showing the new bone-formation over the whole extended region, which was confirmed by hematoxylin & eosin staining with the histological section of A,

DETAILED DESCRIPTION OF THE INVENTION

To achieve the above object, the present invention provides a composition for stimulating bone-formation and bone-consolidation prepared by adding a material stimulating bone-formation and bone-consolidation to the mixture of tripolyphosphate and water-soluble chitosan.

The present invention also provides a use thereof for stimulating bone-formation and bone-consolidation in the early phase.

Further features of the present invention will appear hereinafter.

The present invention provides a composition for stimulating bone-formation and bone-consolidation prepared by adding a material stimulating bone-formation and bone-consolidation to the mixture of tripolyphosphate and water-soluble chitosan.

The composition for stimulating bone-formation and bone-consolidation of the present invention is prepared by adding a material stimulating bone-formation and bone consolidation to the mixture of tripolyphosphate and water-soluble chitosan. β ig-h3, bony morphogenic protein, TGF- β , FGF, IGF-1 and PDGF

are the examples for the material to stimulate bone-formation and bone consolidation, but the examples are not always limited thereto. In the preferred embodiments of the present invention, β ig-h3 and BMP-4
5 were used as materials to stimulate bone-formation and bone-consolidation.

Chitosan is a kind of polysaccharide obtained by deacetylation of chitin, an exoskeleton-structure
10 material of sea Crustacea (Kind, G. M., Bind, S. D., Staren, E. D., Templeton, A. J. and Economou, S. G., *Curr. Surg.*, 47: 37, 1990; Hauschks, P. V., *Bone*, Vol. 1, 103, 1990, London CRC press; Cunningham, N. S., Paralkar, V. and Reddi, A. H., *Proc. Nat. Acad. Sci.*,
15 89: 11740, 1982; Malette, W. G., Quigley, H. J. and Adickes, E. D., *Nature and Technology*, 435: 1986, New York Plenum Press). Muzarelli, etc have disclosed that chitosan introduced to bone-deficient region stimulated normal bone-formation (Muzzarelli, R. A., Mattioli-
20 Belmonte, M., Tiets, C., Biagini, R., Feioli, G., Brunelli, M. A., Fini, M., Giardino, R., Ilari, P. and Biagini, G., *Biomaterials*, 15: 1075, 1994), and Klokkevold, etc also have reported that chitosan stimulated differentiation of bony osteogenesis cells
25 and induced bone-formation itself (Klokkevold, P. R.,

Vandemark, L., Kenney, E. B. and Bernard, G. W., *J. Periodontol.*, 67: 1170, 1996).

5 TGF- β is known to evoke proliferation and differentiation of osteoblasts, especially β ig-h3 is believed to increase the production of various bone intracellular proteins in vitro and decrease the collagen degradation in osteoblasts (Sporn, M. B., Roberts A. B., Springer-Verlag, New York: 3, 1990; Centrella, M., McCarthy, T. L. and Canalis, E., *J. Bone*
10 *Join. Surg.*, 73(Am): 1418, 1991; Mustoe, T. A., Pierce, G. F., Thomason, A., Gramates, P., Sporn, M. B. and Deuel, T. F., *Science*, 237: 1333, 1987; Noda, M. and Camilliere, J. J., *Endocrinol.*, 124: 2991, 1989; Joyce, M. E., Jingski, S., Roberts, A. B., Sporn, M. B. and
15 Bolander, M. E., *J. Bone Miner. Res.*, 4: 225, 1989; Hock, J. M., Canalis, E. and Centrella, M., *Endocrinol.*, 126: 421, 1990; Beck, L. S., Ammann, A. J., Aufdemorte, T. B., DeGuzman, L., Xu, Y., Lee, W. P., McFatridge, L. A. and Chen, T. L., *J. Bone Miner. Res.*, 6: 961, 1991).
20 Among many growth factors, transforming growth factor β (TGF- β) is particularly important regulator for bone-regeneration and development. TGF- β 1 is a strong chemoattractant of osteoblast and leads division of proto-cells of osteoblasts during the endochondrial
25 ossification process. . As a cell-attaching protein

whose expression is induced by TGF- β , β ig-h3 has functions of attaching and spreading cells by working with integrin (Jung-Eun Kim, Song-Ja Kim, Byung-Heon Lee, Rang-Woon Park, Ki-San Kim and In-San Kim, *J. Biol. Chem.*, 275: 30907-30915, 2000) as well as curing a cut. It is also known to play an important role in the early phase of osteogenesis (Dieudonne, S.C., Kerr, J.M., Xu, T., Sommer B., DeRubeis, A.R., Kuznetsov, S.A., Kim, I-S., Robey, P.G., and Young M.F., *J. Cell. Biochem.*, 76: 231-243, 1999).

Bone morphogenic protein (referred as "BMP" hereinafter) is a bone-forming material and was first found by Urist. BMP has been reported to stimulate pluripotential cells to be differentiated into chondrocytes and osteogenesis cells, and also play an important role in bone-regeneration (Urist, M. R., *Science*, 150: 893, 1965; Urist, M. R. and Strates, B. S., *J. Dent. Res.*, 50: 1392, 1971; Wozney, J. M., Butterworth Heineremann 1st Ed. London: 397-411, 1994; Wozney, J. M., *Mol. Reprod. Dev.*, 32; 160, 1992; Wozney, J. M., Rosen, V. and Celeste, A. J., *Science*, 242: 1528, 1988; Ono, I., Tatashita, T., Takita, H. and Kuboki, Y., *J. Craniofac. Surg.*, 7: 418, 1996). 13 human BMPs have been confirmed so far and especially human bone

morphogenic protein-4 (BMP-4) has been reported to have excellent effect on bone-regeneration (Boyne, P. J., Bone, 19: 83s, 1996; Zegzula, H. D., Buck, D. C., Brekke, J., Wozney, J. M. and Hollinger, J. O., *J. Bone*
5 *Join. Surg.*, 79: 1778, 1997; Sporn, M. B., Roberts AB (eds.), *Springer-Verlag*, New York: 3, 1990).

Tripolyphosphate is immediately hardened when water-soluble chitosan is added thereto. Thus, it is
10 required in this invention to inject chitosan, water soluble chitosan containing β ig-h3, a material to stimulate bone-formation and bone-consolidation, or bone morphogenic protein simultaneously into the same spot using dual syringe shown in FIG. 2 in order to
15 induce immediate solidation at the spot, resulting in preventing injected materials from being transferred to other areas.

For the composition for stimulating bone-formation and bone-consolidation of the present
20 invention prepared by adding β ig-h3 or bone morphogenic protein as a material to stimulate bone-formation and bone-consolidation to the mixture of tripolyphosphate and water soluble chitosan,
25 tripolyphosphate and water soluble chitosan are

preferably mixed in the proportion of 20:80 ~ 80:20 weight% and more preferably 50:50 ratio. As a material to stimulate bone-formation and bone-consolidation, β ig-h3 is preferably added to the composition with the amount of 100 $\mu\text{g/ml}$ ~ 1 $\mu\text{g/ml}$ and more preferably with 300 $\mu\text{g/ml}$ ~ 600 $\mu\text{g/ml}$. BMP is also preferably added to the composition with the amount of 50 ng/ml ~ 500 ng/ml and more preferably with 100 ng/ml ~ 300 ng/ml .

10 The present invention also provides a use of the composition for stimulating bone-formation and bone-consolidation in the early phase.

 In order to confirm whether the composition can be used for stimulating bone-formation and bone-consolidation, the present inventors first investigated the effect of the composition prepared by adding water soluble chitosan, water soluble chitosan containing β ig-h3 or water soluble chitosan containing BMP to tripolyphosphate on bone-formation and bone-consolidation as bone-extension operation was performed at the jaw of a dog.

 As a result, in the bone sample of control group obtained 4 weeks and 7 weeks after bone extension, extended area was proved to be solid but a little

flexible when being bended. As for BMP-4 group prepared by adding water soluble chitosan containing BMP-4 to tripolyphosphate, β ig-h3 group prepared by adding water soluble chitosan containing β ig-h3 to tripolyphosphate and chitosan group prepared by adding just water soluble chitosan to tripolyphosphate, extended bone samples taken 4 weeks after bone extension were proved to be more solid than that of control group taken 7 weeks after bone extension. 7 weeks later, new bones were formed and the extended areas became very solid in those groups.

Radio-assay was performed for control group 4 weeks and 7 weeks after bone extension. As a result, wide radiolucent zone was found between extended jaw-spicules and radiodense zone abutting on jaw-spicules was hardly generated. The result obtained 4 weeks after bone extension was not very different from that obtained 7 weeks later in a control group. In the meantime, calcification was clearly observed at the extended area of jaw-bone wherein bone growth materials were introduced in BMP-4group, β ig-h3 group and chitosan group. 4 weeks after introducing bone growth materials, it was confirmed by radio-assay that radiolucent zone between extended jaw-spicules was almost connected with radiodense zone growing from both

sides of spicules. The thickness from top to bottom of radiodense zone became more than two fold 7 weeks later, comparing to that after 4 weeks. Especially, darker radiodense shadow and thicker radiodense zone were
5 observed in the BMP-4 group, comparing to other groups (see FIG. 4 - FIG. 7).

Besides, every group had higher bone-mineral density than control group. Especially, BMP-4 group showed the highest bone-mineral density and β ig-h3
10 group, chitosan group and control group followed in order. Bone-mineral density reflects radiodense level on extended area between jaw-spicules, meaning that the higher the density is the greater new bone-formation becomes (see FIG. 8).

15
Histological test was also performed. As a result, the whole bone-extended area was filled with fibrous tissue 4 weeks later in control group. Although new bone-formation close to jawbone section
20 was begun by periosteum reaction, general bone-formation was not found (see FIG. 9A). 7 weeks later, however, new bone and cartilage-formation were detected near the edge of extended area and blood vessels and nervous tissues were also found in many places (see FIG.
25 9B and 9C).

As for BMP-4 group, the proliferation of osteoblasts forming osteoid was partly observed in center and near the edge of extended spicules, but most parts of the extended area were filled with fibrous tissues 4 weeks later (see FIG. 10A and 10C). 7 weeks later, irregular woven bone trabeculae was partially calcified at extended area, newly formed bone area wherein blood vessels in various sizes were spread and narrow fibrous interzone lying in the middle of the newly formed bone area were observed. The new bone formed throughout the whole extended area was similar to the normal cortical bone (see FIG. 10B and 10D).

As for β ig-h3 group, osteoblasts forming osteoid were partly observed in the center of the extended area, which was confirmed by histological test 4 weeks after bone-extension (see FIG. 11A). 7 weeks later, lots of osteoblasts were partly forming new bone from the edge to the center of extended area. The amount of newly formed bone was smaller than that of BMP-4 group but fibrous interzone locating in the center of extended area was wider than that of BMP-4 group (see FIG. 11B and 11C).

As for chitosan group, histological test 4 weeks later confirmed that most extended area were filled with fibrous tissues (see FIG 12A). 7 weeks later,

lots of osteoblasts along with new bone were observed over the edge of extended area and new bones were confirmed to be formed partly from the edge to the center of extended area (see FIG. 12B and 12C). The
5 amount of newly formed bone in extended area was smaller than that of β ig-h3 group or BMP-4 group, but fibrous interzone was wider than that of β ig-h3 group.

Resultingly, the composition of the present
10 invention which was prepared by adding water soluble chitosan, water soluble chitosan containing β ig-h3, and water soluble chitosan containing BMP-4 to tripolyphosphate can be effectively used for stimulating bone-formation and bone-consolidation by
15 stimulating bone-formation and bone-consolidation in the early phase and by shortening bone-consolidation period.

EXAMPLES

20 Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples.

However, it will be appreciated that those skilled in the art, on consideration of this disclosure,

may make modifications and improvements within the spirit and scope of the present invention.

Example 1: Preparation of composition

5 The present inventors have prepared a composition for stimulating bone-formation and bone-consolidation by adding a material to stimulate bone-formation and bone-consolidation to tripolyphosphate. Particularly, the present inventors prepared a composition by adding
10 0.5 ml of 5% chitosan to 0.5 ml of 5% tripolyphosphate and named it "chitosan group".

Example 2: Preparation of composition

15 The present inventors prepared a composition for stimulating bone-formation and bone-consolidation by adding 0.5 ml of water soluble chitosan containing β ig-h3 at the concentration of 450 μ g/ml to 0.5 ml of 5% tripolyphosphate with the same method as the above Example 1 and named it " β ig-h3 group".

20

Example 3: Preparation of composition

 The present inventors prepared a composition for stimulating bone-formation and bone-consolidation by

adding 0.5 ml of water soluble chitosan containing BMP-4 at the concentration of 200 ng/ml to 0.5 ml of 5% tripolyphosphate with the same method as the above Example 1 and named it "BMP-4 group".

5

Experimental Example 1: Investigating the effect of the compositions of the present invention on bone-formation and bone-consolidation

10 In order to confirm whether the compositions for stimulating bone-formation and bone-consolidation prepared through Example 1 - Example 3 of the present invention can stimulate new bone-formation and bone-consolidation in the early phase, the present inventors first performed bone extension operation at jawbones of
15 dogs, followed by injecting the compositions for stimulating bone-formation and bone-consolidation thereto, and then observed the changes occurring.

Particularly, used 16 5-8 month old dogs for experiments and grouped them by 4 for control group,
20 chitosan group, β ig-h3 group and BMP-4 group.

Kept the breath of dogs through tubes inserted in organs after general anesthesia and shaved the operating part, followed by sterilization and

application. Incised skin 3-4 cm along the lower end of jawbone, lifted masseter muscle and exposed the side part of jawbone. Then, performed vertical osteotomy at the trunk of jawbone using an electric saw and completely cut jawbone. Fixed each fixing pin of external fixator on spicule 1 cm away from the cutting area right and left. While fixing the pins on the jawbone spicule with drill, kept washing with saline solution not to burn the fixing sites. Inserted the pins just as deep as it barely passed through jawbone and then fixed them tightly. After fixing two pins all, set them on bone extending apparatus (Molina Distractors, Wells Johnson Company) (FIG. 1).

Sutured the incised area with 5-0 vicryl and 5-0 nylon stitching fiber layer upon layer and recovered the dogs from anesthesia. Administered penicillin(100,000 μ /kg) by intramuscular injection every 12 hours for 7 days after operation and oral-administered anodyne every 4-6 hours to relieve pain. Fed the dogs with soft diet until the second day after operation and provided regular diet from the third day. From the fifth day after operation, started bone-extension 2 mm per day for 5 days (up to 10 mm total).

On the day when bone extension was finished, injected 5% water soluble chitosan, 5% water soluble chitosan containing BMP-4(200 ng/ml) (R&D System Inc.) and 5% water soluble chitosan containing β ig-h3(450 μ g/ml) with the same amount as 0.5 ml of 5% tripolyphosphate(TPP) simultaneously to the same extended spot using a dual syringe (FIG. 2) for each group to induce immediate hardening by mixing those materials, resulting in the prevention of transferring those injected materials to other areas for strong new bone formation. On the contrary, injected only 1 ml of 5% tripolyphosphate to a control group.

Upon completing the injection of compositions for stimulating bone-formation and bone-consolidation of the present invention to the dogs, kept bone-extending apparatus on them for 7 weeks for bone-consolidation and bone-regeneration. Sacrificed every 2 dogs from each group by injecting overdose of pentobarbital(40-50 mg/kg) 4 weeks after bone extension, so did for the rest 8 dogs 7 weeks after bone extension (FIG. 3).

<1-1> Observation with the naked eye

The changes after the above experiments were observed with the naked eye. Every dogs were well

recovered from anesthesia and operation, bone-extending apparatus was kept stable and no signs of infection around the apparatus were shown. Bone samples taken 4 weeks and 7 weeks after bone extension confirmed that
5 the extended bone area was hardened but a little flexible when being bended in a control group. Meanwhile, 4 week old extended bone areas of BMP-4 group, β ig-h3 group and chitosan group were harder than 7 week old extended bone area of a control group
10 and all the groups except the control group showed very strong and solid new bone formation 7 weeks later.

<1-2> Radio-assay

Examined each animal group went through bone
15 extension with radio-assay every week and observed bone-formation and bone-consolidation through the radiographs taken after 4 weeks and 7 weeks respectively.

As a result, wide radiolucent zone between
20 extended jawbone spicules was seen in a control group both 4 weeks and 7 weeks after bone extension was completed while radiodense zone close to both sides of jawbone spicules was hardly seen 4 weeks later having no difference in result obtained 7 weeks after bone
25 extension. In the meantime, calcification was

undergoing with the lapse of time in extended area of jawbone in every BMP-4 group, β ig-h3 group and chitosan group whereto appropriate material for bone growth was injected. As for those groups, radiolucent zone in between extended spicules was almost connected with radiodense zone growing from each side of spicules, which was confirmed by radiographs taken on the 4th week. On the 7th week, the thickness of radiodense zone became two-fold comparing with that of the 4th week. Especially, the density of radiodense shadow in BMP-4 group was thicker and darker comparing to other groups.

<1-3> Measurement of bone mineral density

Based on radiographs (FIG. 4B, 5B, 6B and 7B) taken on the 7th week in the above Example <1-2>, the present inventors measured bone mineral density with computer program by taking advantage of the fact that radiodense zone becomes brighter on radiograph as bone-formation progresses.

As a result, bone mineral density in those groups was higher than that in control group on the 4th week. Especially, BMP-4 group showed the highest density and β ig-h3 group, chitosan group and control group followed in order (FIG. 8A). BMP-4 group still showed remarkably high density comparing to other groups on

the 7th week and β ig-h3 group, chitosan group and control group also followed in order (FIG. 8B). Bone mineral density reflects the brightness on a radiograph, in other words, the degree of radiodense in extended area between jawbone spicules. Thus, the higher the density, the greater the amount of bone-formation is. Resultingly, it was confirmed that the groups whereto compositions for stimulating bone-formation and bone-consolidation were added showed faster and greater bone-formation than a control group.

<1-4> Histological test

Bone samples were taken from extended jawbone including normal osseous tissues therearound with an electric saw. The obtained spicules were fixed in 10% neutral formalin for 1 week, and then decalcified in 10% nitric acid and 10% sodium citrate for 2 days. 4-6 μ m of specimens were prepared by dehydration and paraffin-fixation following general techniques. The specimens were stained with hematoxylin-eosin to observe histological changes with an optical microscope.

As a result, it was observed in the control group that the whole extended bone area was filled with fibrous tissues and general new bone-formation was not

detected even though new bone-formation by periosteum reaction had just begun along the section of jawbone on the 4th week after bone extension (FIG. 9A). New bone and cartilage were formed over the edge of extended area and blood vessels and nervous tissues were also observed in many places (FIG. 9B and 9C).

As for BMP-4 group, although the proliferation of osteoblasts forming osteoid was partly observed in the center and through the edge of extended spicules, most parts of the extended area were filled with fibrous tissues on the 4th week (FIG. 10A and 10C). On the 7th week, widely formed new bone area having irregular woven bone trabeculae resulted from partial calcification, various sized blood vessels and narrow fibrous interzone lying up and down in the center of new bone area were observed. The new bone formed throughout the whole extended area was almost similar to the normal cortical bone (FIG. 10B and 10D).

As for β ig-h3 group, it was observed on the 4th week that osteoblasts forming osteoid were partly proliferated in the center of the extended area (FIG. 11A). On the 7th week, many active osteoblasts were partly forming new bone from the edge through the center of the extended area, but the volume of new bone was smaller than that of BMP-4 group. The fibrous

interzone lying up and down in the center of the extended area was, though, wider than that of BMP-4 group (FIG. 11B and 11C).

As for chitosan group, most parts of the extended area were filled with fibrous tissues on the 4th week (FIG. 12A). On the 7th week, lots of osteoblasts along with new bone were observed over the edge of the extended area and also new bone was partly formed from the edge through the center of the extended area. The volume of newly formed bone was smaller than those of β ig-h3 group and BMP-4 group but the fibrous interzone was wider than that of β ig-h3 group (FIG. 12B and 12C).

Resultingly, as for BMP-4 group, β ig-h3 group and chitosan group treated with the composition for stimulating bone-formation and bone-consolidation of the present invention, new bone was partly formed in extended area on the 4th week after bone extension and the formation went further on the 7th week. BMP-4 group had the biggest volume of newly formed bone and β ig-h3 group, chitosan group followed in order. Fibrous interzone was found in the center of the extended area in every group on the 7th week. The fibrous interzone of BMP-4 group was the narrowest, β ig-h3 group showed the second narrowest fibrous interzone and chitosan

group was the last. In the meantime, the fibrous interzone took most parts of the extended area in the control group. Observing fibrous interzone still on the 7th week suggests that new-bone formation is still
5 undergoing.

INDUSTRIAL APPLICABILITY

As described hereinbefore, the composition of the present invention prepared by adding a material for
10 stimulating bone-formation and bone-consolidation to the mixture of tripolyphosphate and water-soluble chitosan can be effectively used for stimulating bone-formation and bone-consolidation. Precisely, the composition induces new bone-formation, provides a
15 normal bone-structure, prevents the growth of unnecessary connecting tissues and is suitable enough for human to supplement bone-loss during the recovery process as well as induces the growth of blood vessels and bony osteogenesis cells in the early stage.

20

What is claimed is

1. A composition containing tripolyphosphate and
water-soluble chitosan for stimulating bone-
5 formation and bone-consolidation.
2. The composition for stimulating bone-formation
and bone-consolidation as set forth in claim 1,
wherein the composition could additively contain
10 a material for stimulating bone-formation and
bone-consolidation.
3. The composition for stimulating bone-formation
and bone-consolidation as set forth in claim 2,
15 wherein the material for stimulating bone-
formation and bone-consolidation is selected from
a group consisting of β ig-h3, bone morphogenic
protein, TGF- β , FGF, IGF-1 and PDGF.
- 20 4. The composition for stimulating bone-formation
and bone-consolidation as set forth in claim 1,
wherein the ratio of tripolyphosphate to water-
soluble chitosan is 20:80 ~ 80:20 weight%.

5. The composition for stimulating bone-formation and bone-consolidation as set forth in claim 4, wherein the ratio of tripolyphosphate to water-soluble chitosan is 50:50 weight%.

5

6. The composition for stimulating bone-formation and bone-consolidation as set forth in claim 3, wherein the β ig-h3 is added at the concentration of 100 $\mu\text{g/ml}$ ~ 1 $\mu\text{g/ml}$.

10

7. The composition for stimulating bone-formation and bone-consolidation as set forth in claim 3, wherein the bone morphogenic protein is added at the concentration of 50 ng/ml ~ 500 ng/ml.

15

8. The composition for stimulating bone-formation and bone-consolidation as set forth in claim 6, wherein the β ig-h3 is added at the concentration of 300 $\mu\text{g/ml}$ ~ 600 $\mu\text{g/ml}$.

20

9. The composition for stimulating bone-formation and bone-consolidation as set forth in claim 7, wherein the bone morphogenic protein is added at the concentration of 100 ng/ml ~ 300 ng/ml.

25

10. The composition for stimulating bone-formation and bone-consolidation as set forth in claim 4, wherein the bone morphogenic protein is BMP-4.

1/16


FIGURES

FIG. 1




2/16

FIG. 2



3/16

FIG. 3




4/16

FIG. 4a



FIG. 4b



5/16

FIG. 5a



FIG. 5b




6/16

FIG. 6a



FIG. 6b




7/16

FIG. 7a



FIG. 7b




8/16

FIG. 8a



FIG. 8b



9/16

FIG. 9a






FIG. 9b



10/16

FIG. 9c



11/16

FIG. 10a




FIG. 8b



12/16

FIG. 10c





FIG. 10d



13/16

FIG. 11a





FIG. 11b



14/16

FIG. 11c



15/16

FIG. 12a



FIG. 12b



16/16

FIG. 12c



INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR02/01837**A. CLASSIFICATION OF SUBJECT MATTER****IPC7 A61L 27/14**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61L 27/14, A01N 25/12, A01N 43/04, A61F 2/00, A61K2/14, A61M 5/32

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean Patent and Application for Invention since 1975

Korean Utility Models and Application for Utility Models since 1975

Japanese Utility Models and Application for Utility Models since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

NCBI, eKIPASS, USPTO, INSPECT "tripolyphosphate, chitosan, bone, composition, form*"

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6344488 B1 (Bio Syntec) 5 Feb 2002 -see the whole document, especially Example V-	1, 2, 4, 5
A	Biomaterials, Vol. 20:1603-1612 (Mi, et al.) Sep 1999 -see the whole document-	1, 4, 5
A	International Journal of Pharmaceutics, Vol. 233: 217-225 (Shu, X.Z. and Zhu, K.J.) Feb 2002 -see the whole document-	1, 4, 5
T, A	J Clin Invest, Vol. 110: 751-759 (Peng, et al.) Sep 2002 -see the whole document-	1, 3, 7, 9, 10
A	Bone, Vol. 31: 340-347 (Kishimoto, et al.) Aug 2002 -see the whole document-	1, 3, 7, 9, 10

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

25 JUNE 2003 (25.06.2003)

Date of mailing of the international search report

26 JUNE 2003 (26.06.2003)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

JOO, Young Sik

Telephone No. 82-42-481-5995



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR02/01837

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6344488 B1	5 Feb 2002	WO 9907416 A1 EP 1003567 A1 AU 724878 B2 JP 2001513367 T2 NZ 502919 A IL 134368 A0 NO 20000593 A	18 Feb 1999 31 May 2000 05 Oct 2000 04 Sep 2001 26 Apr 2002 30 Apr 2001 29 Mar 2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.